Reviewed August 2026 by the Corydalis Labs Technical Team. How we research and review.
Where the category actually stands
If you sell botanical products and your best-performing SKU was built on 7-hydroxymitragynine, the last eighteen months have been unpleasant, and the advice available online has largely made it worse. Most of the articles ranking for "7-OH alternatives" were published before July 2026 and recommend compounds that have since been named in federal scheduling actions.
So before anything else, the current state of play:
| Compound | Source | Status | Practical effect |
|---|---|---|---|
| 7-OH 7-hydroxymitragynine | Mitragynine derivative | DEA notice, Jul 2026 | Exiting. Already Schedule I in some states. |
| Pseudoindoxyl mitragynine pseudoindoxyl | Mitragynine derivative | DEA notice, Jul 2026 | Exiting. Named in the same action. |
| MGM-15 also sold as Oxonol | Semi-synthetic | DEA notice, Jul 2026 | Exiting. Named in the same action. |
| Mitragynine standard kratom extract | Mitragyna speciosa | Unscheduled federally | Still sellable, still subject to state kratom acts. No differentiation. |
| 13-OH 13-OH Corydalis Yanhusuo | Corydalis yanhusuo | Not scheduled | Outside the mitragynine chemistry entirely. Outside state kratom acts. |
The pattern worth noticing
Look at the source column. 7-OH, pseudoindoxyl, and MGM-15 are all built on mitragynine. That is not a coincidence — it is the mechanism. Once regulators are examining a chemical family, derivatives of that family inherit the scrutiny. Each successive replacement bought the category less time than the one before it.
Any replacement drawn from the same chemistry is, at best, a shorter version of the same cycle. That is the thing to weigh when you are choosing what to reformulate into: not whether a compound is legal this quarter, but whether the reason it is legal is durable.
The test we would apply
Ask of any candidate ingredient: does its parent chemistry have a scheduling history? If the answer is yes, you are building on a foundation regulators have already shown interest in. If the answer is no, there is no existing listing for a derivative rule to attach to, and the compound has to be evaluated on its own terms — a far slower process.
What sits outside the pattern
13-OH is derived from Corydalis yanhusuo, a plant used in traditional herbal practice for centuries and with no scheduling history at any level of United States government. Its parent alkaloid, tetrahydropalmatine, is an isoquinoline — a structural family entirely separate from the indole alkaloids of the kratom leaf — and is not scheduled either.
It is also not a "kratom product" for the purposes of state law. Those statutes define their scope around Mitragyna speciosa; a formulation containing 13-OH and no kratom material falls outside them. State-by-state detail here.
What it is not is a drop-in replacement that behaves like 7-OH. We would rather be straight with you about that than sell you a disappointment. 13-OH is a synergist: at 25–40 mg per serving it improves a blend substantially, and on its own at those levels it is subtle. The brands succeeding with it are using it to make a mitragynine product distinctly better, or to build kratom-free products that were not possible before. What 13-OH actually is.
Three viable paths
1. Keep mitragynine, add 13 to differentiate
The lowest-friction move. Your existing SKU, your existing compliance posture, with 13-OH added at 25–40 mg per serving. The product reads and performs differently from every mitragynine-only competitor, and the same target profile can be met at a lower mitragynine inclusion. How MIT + 13 works.
2. Build kratom-free
Kava, kanna, and 13-OH, with no Mitragyna speciosa material at all. No state kratom act applies, which opens retail channels that have dropped the category entirely. The kratom-free path.
3. Run both
Most of the brands we work with end up here — a differentiated mitragynine line for the customers they have, and a kratom-free line for the channels they could not previously reach.
How to actually do the reformulation
We wrote a step-by-step version of this: how to map your current spec, choose an inclusion rate, run a bench comparison against your existing product, and handle labelling. The reformulation playbook is here.
Common questions
FDA issued warning letters to firms marketing 7-hydroxymitragynine products, and in July 2026 DEA filed notices of intent to temporarily place 7-OH into Schedule I. Several states, including Florida, moved earlier through emergency scheduling. The practical effect for brands is that 7-OH-based products are exiting the market. The tracker has current status.
No — both were named in the same July 2026 DEA notices. Articles recommending them as 7-OH replacements were written before that action and have not been updated. If you pivoted to either, you pivoted into the same problem on a shorter timeline. What happened to each.
Every compound listed above is built on mitragynine — chemistry that regulators were already examining. 13-OH is derived from Corydalis yanhusuo, a plant with no scheduling history at any level, and its parent alkaloid tetrahydropalmatine is not scheduled either. There is no existing listing for a derivative rule to attach to. That is a structural difference, not a timing difference.
Nothing about the 7-OH actions makes ordinary mitragynine products unlawful federally, and they remain subject to the same state kratom acts as before. Many brands are keeping their mitragynine line and adding 13-OH to differentiate it, rather than replacing the line wholesale. That is the MIT + 13 approach.
That depends mostly on packaging. Our co-packing lead time is fifteen days from the point your packaging arrives with us, so brands with artwork ready and components on order move quickly. Demand is rising and lead times lengthen as the queue fills, so the earlier a spec is locked the earlier a production slot is held. Co-packing detail.